MedTrace Logo

Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab

NCT01436617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 303

Last updated 2013-03-08

No results posted yet for this study

Summary

The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and thus reduce the incidence of severe reactions.

Conditions

Interventions

OTHER

blood sample

The IgE anti cetuximab test will then be conducted by an ELISA test

Sponsors & Collaborators

  • University Hospital, Caen

    collaborator OTHER

  • Centre Francois Baclesse

    lead OTHER

Principal Investigators

  • GERVAIS Radj, MD · Centre François Baclesse

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01436617 on ClinicalTrials.gov